|Bid||123.58 x 800|
|Ask||127.55 x 800|
|Day's Range||125.18 - 127.45|
|52 Week Range||86.88 - 154.24|
|Beta (5Y Monthly)||1.19|
|PE Ratio (TTM)||53.63|
|Earnings Date||Nov 03, 2020 - Nov 09, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||163.59|
Jazz Pharmaceuticals (JAZZ) reports better-than-expected second-quarter 2020 earnings and revenues. It raises its guidance for 2020. Shares rise.
Jazz Pharmaceuticals (NASDAQ: JAZZ) hasn't given investors much good news so far in 2020. The drugmaker's first-quarter results announced in May were disappointing. Jazz stock has dropped 23% year to date.
Jazz (JAZZ) delivered earnings and revenue surprises of 9.76% and 11.06%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2020 and updated its 2020 financial guidance.
Jazz Pharmaceuticals (NASDAQ: JAZZ) announces its next round of earnings this Tuesday, August 04. Here is Benzinga's everything-that-matters guide for this Tuesday's Q2 earnings announcement.Earnings and Revenue Based on management's projections, Jazz Pharmaceuticals analysts model for earnings of $3.13 per share on sales of $501.95 million. In the same quarter last year, Jazz Pharmaceuticals reported EPS of $4.050 on revenue of $534.13 million. If the company were to report in-line earnings when it publishes results Tuesday, earnings would be down 22.72%. Revenue would have fallen 7.66% from the same quarter last year. Here's how the company's EPS has stacked up against analyst estimates in the past:Quarter Q1 2020 Q4 2020 Q3 2019 Q2 2019 EPS Estimate 0.67 4.12 3.59 3.58 EPS Actual 0.45 4.42 4.10 4.05 Revenue Estimate 543.59 M 561.69 M 525.16 M 508.83 M Revenue Actual 534.73 M 581.74 M 537.70 M 534.13 M Stock Performance Over the last 52-week period, shares are down 22.75%. Given that these returns are generally negative, long-term shareholders are probably down going into this earnings release.View more earnings on JAZZDon't be surprised to see the stock move on comments made during its conference call. Jazz Pharmaceuticals is scheduled to hold the call at 16:30:00 ET and can be accessed here: https://edge.media-server.com/mmc/p/nxixrvtiSee more from Benzinga * Looking Into Texas Roadhouse's Return On Capital Employed * ROCE Insights For Hyatt Hotels * ROCE Insights For CVR Energy(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution on July 21, 2020 for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.1,2 Xywav is an oxybate product with a unique composition of cations resulting in 92 percent less sodium – or approximately 1,000 to 1,500 mg/night – than sodium oxybate at the recommended dosage range of 6 to 9 grams.1
|Upgrade||Wolfe Research: Peer Perform to Outperform||7/28/2020|
|Upgrade||HC Wainwright & Co.: Neutral to Buy||7/23/2020|
|Maintains||B of A Securities: to Buy||6/18/2020|
|Maintains||SVB Leerink: to Outperform||6/1/2020|
|Maintains||SunTrust Robinson Humphrey: to Buy||5/6/2020|
|Maintains||BMO Capital: to Outperform||5/6/2020|